Cetuximab After Immunotherapy for the Treatment of Head and Neck Squamous Cell Cancer
Phase 2 Recruiting
38 enrolled
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
Phase 2 Recruiting
188 enrolled
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
Phase 1 Recruiting
51 enrolled
Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer
Phase 1 Recruiting
46 enrolled
IC Plus Low-dose Radiation Plus Cadonilimab in LANPC
Phase 3 Recruiting
380 enrolled
Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
Phase 2 Recruiting
156 enrolled
A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)
Phase 2 Recruiting
50 enrolled
A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients
Phase 3 Recruiting
500 enrolled
Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer
Phase 3 Recruiting
420 enrolled
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
Phase 3 Recruiting
158 enrolled
A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone
Phase 1 Recruiting
90 enrolled
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Phase 1 Recruiting
18 enrolled
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
Phase 2 Recruiting
150 enrolled
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Phase 1/2 Recruiting
233 enrolled
Lenvatinib 24 mg/Day Versus 10 mg/Day to Treat Symptomatic or Progressive Radioactive Iodine Resistant (RAIR) Differentiated Thyroid Cancer (DTC)
Phase 2 Recruiting
34 enrolled
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
Phase 1/2 Recruiting
60 enrolled
Toripalimab Combined With Different Platinum-Based Induction Chemotherapy Regimens for Locally Advanced Nasopharyngeal Carcinoma
Phase 2 Recruiting
243 enrolled
Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC
Phase 3 Recruiting
266 enrolled
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
Phase 2/3 Recruiting
613 enrolled
Study of De_Intensified Postoperative Radiation Therapy for HPV Associated Oropharyngeal Squamous Cell Carcinoma
Phase NA Recruiting
111 enrolled
JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
Phase 3 Recruiting
500 enrolled
The Role of 68-Gallium-DOTATATE-PET/CT in the Imaging of Metastatic Thyroid Cancer
Phase 2 Recruiting
54 enrolled
DIREKHT2
Phase 2/3 Recruiting
508 enrolled
Feasibility Study of CBCT for IGRT in Cancer Patients
Phase NA Recruiting
50 enrolled
LUMIRAY
Phase 1 Recruiting
30 enrolled
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Phase 1/2 Recruiting
300 enrolled
STELLAR-002
Phase 1 Recruiting
1,314 enrolled
PNeoVCA
Phase 1/2 Recruiting
132 enrolled
Losartan, Pembrolizumab and Stereotactic Body Radiation Therapy for the Treatment of Patients With Locally Recurrent, Refractory or Oligometastatic Head and Neck Squamous Cell Carcinoma
Phase 1 Recruiting
24 enrolled
Phase II Trial of Sacituzumab Govitecan in Recurrent and/or Metastatic Secretory Gland Cancers
Phase 2 Recruiting
30 enrolled
Efficacy and Safety Evaluation of VS-101 in Combination With Chemoradiotherapy in Patients With Head and Neck Cancer
Phase 2 Recruiting
30 enrolled
Palliative Steroeotactic Body Radiotherapy vs Palliative Standard Radiotherapy in Patients With Advanced Head and Neck Cancer
Phase 3 Recruiting
196 enrolled
A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
Phase 1 Recruiting
76 enrolled
Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer
Phase 2 Recruiting
224 enrolled
A Study of Reduced Radiation Therapy and Standard-of-Care Chemotherapy in People With HPV-Positive Throat Cancer
Phase 2 Recruiting
121 enrolled
Digi-Coach
Phase NA Recruiting
138 enrolled
A Study of Reduced Radiation Therapy With Chemotherapy in People With HPV-Positive Throat Cancer
Phase 2 Recruiting
74 enrolled
(NeoScorch HN)
Phase 2 Recruiting
75 enrolled
Proton Therapy for Recurrent Nasopharyngeal Carcinoma
Phase NA Recruiting
52 enrolled
A Study Testing Emactinib Sulfate With Chemotherapy and Immunotherapy Before Surgery for Advanced Head and Neck Cancer
Phase 2 Recruiting
76 enrolled
Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response
Phase 3 Recruiting
593 enrolled
HoT
Phase NA Recruiting
456 enrolled
A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
Phase 1 Recruiting
46 enrolled
HN-Quest
Phase NA Recruiting
173 enrolled
HN-BIO
Phase NA Recruiting
60 enrolled
Antibiotic Treatment Effects on Intratumoral Bacteria Modulation in Surgical Patients With Oral Cancer
Phase 2 Recruiting
30 enrolled
FORTIFI-HN01
Phase 2/3 Recruiting
650 enrolled
STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers
Phase 1/2 Recruiting
188 enrolled
The PhOCus Trial: Implementation of Pharmacogenomic Testing in Oncology Care
Phase NA Recruiting
860 enrolled
TheraT® Vectors (Vaccines) Combined With Chemotherapy to Treat HPV16 Head and Neck Cancers
Phase 1/2 Recruiting
98 enrolled